Underserved therapeutic classes: Examples which should not be ignored in infants and children

Drug Information Journal

Volumn 30, Issue 4, 1996, Pages 1179-1186

  Wells, Thomas G ^a  

^a ARKANSAS CHILDREN S HOSPITAL   (United States)

Author keywords

Children; Pediatric labeling; Underserved therapeutic classes

Indexed keywords

ANTIASTHMATIC AGENT; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIHYPERTENSIVE AGENT; ANTIPYRETIC AGENT; CAPTOPRIL; HUMAN GROWTH HORMONE; INSULIN; ISRADIPINE; LUNG SURFACTANT; MERCAPTAMINE; NEW DRUG; SUCCIMER; VACCINE;

CHILD; CLINICAL PROTOCOL; CLINICAL TRIAL; DOSE RESPONSE; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG INDUSTRY; DRUG INFORMATION; DRUG LABELING; DRUG SAFETY; DRUG SCREENING; FOOD AND DRUG ADMINISTRATION; GOVERNMENT; HEALTH CARE DELIVERY; HUMAN; HYPERTENSION; INFANT; MEDICAL ETHICS; NEWBORN; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; UNITED STATES;

EID: 0029830349     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286159603000437     Document Type: Review

References (24)

1. Wilson JT, Kearns GL, Murphy D, Yaffe SJ. Paediatric Labeling Requirements: Implications for Pharmacokinetic Studies. Clin Pharmacokinet. 1994; 26(4):308-325.
2. Farrar HC, Wells TG, Kearns GL. Paediatric Clinical Pharmacology: Reclaiming the Therapeutic Orphan. Exp Opin Invest Drugs. 1996;5(1):7-13.
3. Wilson JT. Pragmatic Assessment of Medicines Available for Young Children and Pregnant or Breast-Feeding Women. In: Morselli PL et al., eds. Basic and Therapeutic Aspects of Perinatal Pharmacology. New York: Raven Press; 1975:76-112.
4. Offices of Drug Evaluation Statistical Report, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD. U.S. Department of Health and Human Services Publication 89-233530, 1989.
5. Committee on Drugs. Guidelines for the Ethical Conduct of Studies to Evaluate Drugs in Pediatric Populations. Pediatrics. 1995;95(2):286-294.
6. Physicians Desk Reference. 48th Edition, Supplements A & B. Montvale, NJ: Medical Economics Data Production Company; 1995.
7. Gilman JT, Gal P. Pharmacokinetic and Pharmacodynamic Data Collection in Children and Neonates: A Quiet Frontier. Clin Pharmacokinet. 1992;23(1): 1-9.
8. Besunder JB, Reed MD, Blumer JL. Principles of Drug Biodisposition in the Neonate: A Critical Evaluation of the Pharmacokinetic-Pharmacodynamic Interface (Part I). Clin Pharmacokinet. 1988;14: 189-216.
9. Besunder JB, Reed MD, Blumer JL. Principles of Drug Biodisposition in the Neonate: A Critical Evaluation of the Pharmacokinetic-Pharmacodynamic Interface (Part II). Clin Pharmacokinet. 1988;14: 261-286.
10. Spielberg SP. Opportunities for Pediatric Drug Development: The Knowledge Bridge from Basic Science to Clinical Application. Drug Inf J. 1996;30(3).
11. Anderson TT, Lee CKK. Formulary. In: Johnson KB, ed. The Harriet Lane Handbook. 13th Edition. St. Louis, MO: Mosby; 1993:363-596.
12. Sehic A, Chesney RW. Acute Renal Failure: Therapy. Pediatr Rev. 1995;16(4):137-141.
13. Miller K. Pharmacological Management of Hypertension in Paediatric Patients: A Comprehensive Review of the Efficacy, Safety, and Dosage Guidelines of the Available Agents. Drugs. 1994;48(6):868-887.
14. Lieberman E. Pediatric Hypertension: Clinical Perspective. Mayo Clin Proc. 1994;69(11):1098-1107.
15. Tack ED, Perlman JM. Renal Failure in Sick Hypertensive Premature Infants Receiving Captopril Therapy. J Pediatr. 1988;112(5):805-810.
16. Perlman JM, Volpe JJ. Neurologic Complications of Captopril Treatment of Neonatal Hypertension. Pediatrics. 1989;83(1):47-52.
17. Scammell AM, Arnold R. The Effect of the First Dose of Captopril on Blood Pressure in Infants in Heart Failure. Int J Cardiol. 1989;22:377-379.
18. Arkansas Vital Statistics 1993, Arkansas Department of Health Center for Health Statistics and the Division of Vital Records, Little Rock, Arkansas. December 1994.
19. Sinaiko AR, Wells TG. Childhood Hypertension. In: Laragh JH, Brenner BM (eds). Hypertension: Pathophysiology, Diagnosis and Management. New York: Raven Press; 1990: 1853-1868.
20. The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. National High Blood Pressure Education Program, National Heart Lung and Blood Institute, National Institutes of Health, Publication No. 93-1088, 1993.
21. Rüegg UT, Hof RP. Pharmacology of the Calcium Antagonist Isradipine. Drugs. 1990;40(Suppl. 2): 3-9.
22. Frishman WH. Calcium-Channel Entry Blocker Therapy for Hypertensive Patients with Concomitant Renal Impairment: A Focus on Isradipine. J Clin Pharmacol. 1994;34:1164-1172.
23. Wells TG, House M, Belsha CW, Berry PL. Isradipine Treatment of Hypertension in Children. J Investigative Med. 1995;43:59.
24. Specific Requirements on Content and Format of Labeling for Human Prescription Drugs; Revision of "Pediatric Use" Subsection in the Labeling. Food and Drug Administration, Department of Health and Human Services. Federal Register. 1994;59(238): 64240-64250.